- Home
- BKNG vs AMGN Comparison
BKNG vs AMGN Comparison
Compare BKNG & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKNG
- AMGN
- Stock Information
- Founded
- BKNG 1997
- AMGN 1980
- Country
- BKNG United States
- AMGN United States
- Employees
- BKNG N/A
- AMGN N/A
- Industry
- BKNG Transportation Services
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BKNG Consumer Discretionary
- AMGN Health Care
- Exchange
- BKNG Nasdaq
- AMGN Nasdaq
- Market Cap
- BKNG 163.6B
- AMGN 152.1B
- IPO Year
- BKNG 1999
- AMGN N/A
- Fundamental
- Price
- BKNG $5,177.15
- AMGN $294.53
- Analyst Decision
- BKNG Buy
- AMGN Buy
- Analyst Count
- BKNG 33
- AMGN 22
- Target Price
- BKNG $4,741.77
- AMGN $334.58
- AVG Volume (30 Days)
- BKNG 273.4K
- AMGN 2.9M
- Earning Date
- BKNG 10-30-2024
- AMGN 10-30-2024
- Dividend Yield
- BKNG 0.68%
- AMGN 3.06%
- EPS Growth
- BKNG 2.91
- AMGN N/A
- EPS
- BKNG 145.91
- AMGN 7.83
- Revenue
- BKNG $23,052,000,000.00
- AMGN $32,534,000,000.00
- Revenue This Year
- BKNG $11.95
- AMGN $20.06
- Revenue Next Year
- BKNG $8.67
- AMGN $3.50
- P/E Ratio
- BKNG $35.48
- AMGN $37.60
- Revenue Growth
- BKNG 11.74
- AMGN 21.25
- 52 Week Low
- BKNG $3,079.50
- AMGN $260.68
- 52 Week High
- BKNG $5,216.00
- AMGN $346.85
- Technical
- Relative Strength Index (RSI)
- BKNG 75.86
- AMGN 40.27
- Support Level
- BKNG $4,907.03
- AMGN $275.56
- Resistance Level
- BKNG $5,029.43
- AMGN $328.25
- Average True Range (ATR)
- BKNG 92.76
- AMGN 8.54
- MACD
- BKNG 2.97
- AMGN -1.82
- Stochastic Oscillator
- BKNG 91.29
- AMGN 36.00
About BKNG Booking Holdings Inc.
Booking is the world's largest online travel agency by sales, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates several branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.